Local Version of the Multi-center PREVENT Study Evaluating Cardio-respiratory Instability in Premature Infants
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03655639 |
|
Recruitment Status :
Recruiting
First Posted : August 31, 2018
Last Update Posted : June 21, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Premature Birth |
The broad long-term objective is to use comprehensive state-of-the-art, high-fidelity monitoring to investigate physiological biomarkers of autonomic neurorespiratory maturation with integrated analysis of autonomic nervous system (ANS) responses in preterm infants, and to evaluate their role in ventilatory instability, bronchopulmonary dysplasia (BPD), and co-morbidities including neurodevelopment in the 1st year of life. SPECIFIC AIM 1 will establish the spectrum and developmental trajectory of ANS maturation/function using high-resolution physiologic recordings of ventilatory, cardiovascular, and cerebrovascular measures during typical daily activity (28, 32 and 36 weeks (wks) post-menstrual age (PMA)(up to 24-hour recordings) and at 3 and 12 months (mos) corrected age (CA)(4-hour recordings). Aim 1 tests the hypothesis that individual and integrated metrics of ANS function will demonstrate maturational patterns that impart resilience or vulnerability to environmental challenges. SPECIFIC AIM 2 will determine respiratory and neurodevelopmental morbidity throughout the 1st year of life using clinically applicable outcome measures and associate morbidity with ANS development and function using a Respiratory Morbidity Severity Score (RMSS), need for respiratory support, medications, or hospitalization, Bayley Scales of Infant Development III (6, 12 mos), Neurological, Sensory, Motor, Developmental Assessment (NSMDA)(3, 6, 12 mos), and early measures of evoked-auditory potentials (EAP)(28, 32, 36 wks PMA; 3, 12 mos CA) and General Movement Assessments (GMA)(28, 32, 36 wks; 3 mos). Aim 2 tests the hypothesis that infants demonstrating delayed ANS maturation or vulnerability to endogenous challenges will require more respiratory interventions and will demonstrate developmental delays in the 1st year of life. SPECIFIC AIM 3 will determine endotypes of autonomic neurorespiratory stability and maturation through trajectory analysis and integrated physiological modeling. Aim 3 tests the hypothesis that trajectory analysis will reveal 3 autonomic maturation patterns [1) "normal" maturation with ability to withstand environmental perturbations; 2) "normal" maturation without ability to withstand environmental perturbations; and 3) delayed or disordered maturation with inability to maintain physiologic stability in absence of environmental perturbations] that will be associated with severity of respiratory morbidity and neuromotor impairment at 1 year. This novel approach will establish the role of autonomic neurorespiratory maturation in stability of oxygenation throughout the 1st year of life, provide insight into BPD pathogenesis, allow prospective identification of at-risk infants, and permit development of mechanism-specific interventions with potential to impact thousands of families and billions in healthcare cost/year in the U.S., alone.
In addition to lung-independent mechanisms of respiratory dysfunction, this study aims to investigate lung-independent mechanisms of pulmonary hypertension (PH). Typically thought to be a secondary effect of primary lung structural development and/or hypoxia, up to 40% of infants with chronic respiratory dysfunction develop pulmonary hypertension (PH) and increased risk for mortality. However, we and others found that 10-30% of premature infants who develop PH did not have clinical evidence of respiratory dysfunction, suggesting pulmonary vascular mechanisms that are independent of clinically apparent respiratory disease. Multiple molecular mechanisms are postulated by which hypoxia results in PH, but preliminary data from our group and others suggest a role for Fibroblast Growth Factor 2 (FGF2) and FGF receptors 1 and 2 (FGFR1, FGFR2) signaling in the development of pulmonary vascular remodeling in PH. Thus, by serially using sensitive echocardiographic measures of Right Ventricular-Pulmonary Arterial (RV-PA) coupling, we can quantify hypoxic exposure and RV-PA axis dysfunction and we will couple these clinical measurements of FGF2 signaling. We hypothesize that recurrent hypoxic exposure of dysmature pulmonary vasculature in premature newborns results in RV-PA axis dysfunction and pulmonary hypertension that is mediated by FGF2 signaling and is independent of clinically apparent lung disease.
| Study Type : | Observational |
| Estimated Enrollment : | 120 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Evaluating Cardiorespiratory Development in Premature Babies |
| Actual Study Start Date : | June 1, 2018 |
| Estimated Primary Completion Date : | December 31, 2022 |
| Estimated Study Completion Date : | December 31, 2022 |
| Group/Cohort |
|---|
|
Premature Birth
Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
|
- Change in cardiorespiratory coupling between 28 weeks postmenstrual age and 1 year [ Time Frame: 1 year ]Average cross-spectral coherence between heart rate and respiratory rate summed within the high frequency band (above 0.15 Hz; ratiometric units). Higher coherence indicates better coupling.
- Neurodevelopmental outcomes as measured with the Neurological, Sensory, Motor, Developmental Assessment (NSMDA) functional grade [ Time Frame: 1 year ]6 subtests are scored individually (1-5 with 1 being normal, 5 with profound disability) and added together - normal 6-8, 9-11 minimal dysfunction, 12-14 mild problems, 16-19 moderate disability, 20-24 severe disability and 25-30 multiple, severe or profound disabilities.
- Change in right ventricle-pulmonary circulation (RV-PC) axis function between 32 and 36 weeks postmenstrual age [ Time Frame: 36 weeks postmenstrual age ]echocardiographic measurements of pulmonary artery acceleration time (PAAT, milliseconds), where values less than 43 msec are indicative of RV-PC axis dysfunction
- Changes in circulating levels of fibroblast growth factor 2 (FGF2) and granulocyte macrophage colony stimulating factor (G-CSF) between 32 and 36 weeks postmenstrual age [ Time Frame: 36 weeks postmenstrual age ]comparison of FGF2 and G-CSF levels as measured by immunoassay between infants with and without RV-PC axis dysfunction
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 24 Weeks to 29 Weeks (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- birth between 24 and 29 weeks of gestation
- less than 1 week of age
Exclusion Criteria:
- known congenital anomalies
- imminent death
- factors that preclude reliable follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03655639
| Contact: Aaron Hamvas | 312-227-1400 | ahamvas@luriechildrens.org | |
| Contact: Debra Weese-Mayer | 312-227-3300 | dweese-mayer@luriechildrens.org |
| United States, Illinois | |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Recruiting |
| Chicago, Illinois, United States, 60611 | |
| Contact: Erin Lonergan, BHS 312-227-1000 ext 3315 Ersmith@luriechildrens.org | |
| Northwestern Memorial Hospital | Recruiting |
| Chicago, Illinois, United States, 60611 | |
| Contact: Erin Lonergan, BHS 312-227-1000 ext 3315 Ersmith@luriechildrens.org | |
| Principal Investigator: | Aaron Hamvas | Ann & Robert H Lurie Children's Hospital of Chicago |
| Responsible Party: | Ann & Robert H Lurie Children's Hospital of Chicago |
| ClinicalTrials.gov Identifier: | NCT03655639 |
| Other Study ID Numbers: |
2017-1178 U01HL133704 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 31, 2018 Key Record Dates |
| Last Update Posted: | June 21, 2021 |
| Last Verified: | June 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications |